Effects of Pravastatin in Short-term Treatment of Congestive Heart Failure on Inflammatory Factors

LI Yanfang,WANG Xiuying,ZHANG Yi,XIONG Qingyun,PENG Daoquan
DOI: https://doi.org/10.3969/j.issn.1674-4659.2011.01.0042
2011-01-01
Abstract:Objective To investigate the effects ofpravastatin in short-term treatment ofpatients with congestive heart failure(CHF) on tumornecrosisfactor-α(TNF-α),highsensitivityC-reactive protein(hs-CRP) as well as IL-6.The peripheral blood mononuclear cells(PBMC) were isolated to measure the supernatant IL-6 after treatment with pravastatin.Methods A total of 32 patients with CHF were randomly divided into pravastatin group(pravastatin 20 mg/d) on top of standard therapy(n=18) and control group(standard therapy,n=14) and followed two weeks.The changes on cardiac function,plasma TNF-α level,hs-CRP,and IL-6 were determined before and after therapy,at the same time,IL-6 secretion were measured by PBMC culturing.The levels of TNF-α,IL-6 in plasma and IL-6 in supernatants of PBMC were measured by enzyme-linked immunosorbent assay(ELISA).Results The serum cholesterol level decreased significantly after two weeks' treatment with pravastatin(P 0.05).No significant changes in LVEF were observed in both control and treatment groups.The levels of hs-CRP,TNF-α and IL-6 decreased significantly in both groups after 2 weeks' treatment(P 0.01),and the decreases were more prominent in the pravastatin group compared to the control group(P 0.05).IL-6 secretion by PBMC from patients with CHF decreased in both groups(P 0.01),with more decrease in the pravastatin group compared to control group(P 0.05).Conclusion Pravastatin in short-term treatment of CHF can reduce the plasma levels of TNF-α,hs-CRP,and IL-6,in addition,pravastatin significantly inhibites IL-6 secretion by PBMC from patients with CHF,which may contribute to the anti-inflammatory effect of pravastatin.
What problem does this paper attempt to address?